The Experts below are selected from a list of 282 Experts worldwide ranked by ideXlab platform
Lewis J. Smith - One of the best experts on this subject based on the ideXlab platform.
-
Sulfasalazine-induced Pulmonary Disease.
Chest, 1992Co-Authors: M. Abdulgany Hamadeh, Janis Atkinson, Lewis J. SmithAbstract:We report the findings in two patients with sulfasalazine-induced Pulmonary Disease. The first patient developed Pulmonary interstitial fibrosis after more than 4 yr of treatment for Crohn's Disease. Pulmonary symptoms and chest roentgenographic and Pulmonary function abnormalities gradually reversed after stopping the drug. No specific treatment was given. The second patient, who had rheumatoid arthritis without Pulmonary Disease, received the drug for 1 yr without experiencing any problems. Readministration seven months later resulted in the development of an acute interstitial Pulmonary Disease. Discontinuing the drug and treatment with corticosteroids produced rapid improvement. We discuss these patients in relation to other reports of sulfasalazine-induced Pulmonary toxicity, highlighting their atypical features.
Won-jung Koh - One of the best experts on this subject based on the ideXlab platform.
-
treatment with a macrolide containing regimen for mycobacterium kansasii Pulmonary Disease
Respiratory Medicine, 2019Co-Authors: Seong Mi Moon, Charles L. Daley, Junsu Choe, Byung Woo Jhun, Kyeongman Jeon, Jung O Kwon, Hee Jae Huh, Nam Yong Lee, Won-jung KohAbstract:Abstract Background Mycobacterium kansasii is a major pathogen associated with nontuberculous mycobacterial Pulmonary Disease. For treatment of M. kansasii Pulmonary Disease, daily therapy with isoniazid, rifampin, and ethambutol is traditionally recommended. Although a regimen containing a macrolide, instead of isoniazid, has been recently recommended, supporting data are limited. We compared the treatment outcomes of a macrolide-containing regimen (macrolide group) and an isoniazid-containing regimen (isoniazid group) on patients with M. kansasii Pulmonary Disease. Methods A total of 49 patients were identified between January 2002 and December 2016. Treatment outcomes for the isoniazid group (n = 24) and the macrolide group (n = 25) were compared. Results Baseline characteristics of the isoniazid and macrolide groups were similar. Favorable outcomes did not differ between the isoniazid group (79%, n = 19) and macrolide group (88%, n = 22, P = 0.463). Total treatment duration (median 17.9 months vs. 15.4 months; P = 0.712) and time to culture conversion (median 2.0 months vs. 1.2 months; P = 0.838) were also similar between the isoniazid and macrolide groups. Five patients who completed three-times-weekly intermittent treatment containing a macrolide for non-cavitary M. kansasii Pulmonary Disease achieved negative sputum culture conversion within 12 months of treatment. Only one patient experienced recurrence of M. kansasii Pulmonary Disease in the isoniazid group. Conclusions A macrolide-containing regimen appears to be as effective as an isoniazid-containing regimen for treatment of M. kansasii Pulmonary Disease. Additionally, intermittent therapy containing a macrolide could be an alternative treatment option for non-cavitary M. kansasii Pulmonary Disease.
-
Treatment of Mycobacterium avium Complex Pulmonary Disease
Tuberculosis and respiratory diseases, 2019Co-Authors: Yong Soo Kwon, Won-jung Koh, Charles L. DaleyAbstract:The pathogen Mycobacterium avium complex (MAC) is the most common cause of nontuberculous mycobacterial Pulmonary Disease worldwide. The decision to initiate long-term antibiotic treatment is difficult for the physician due to inconsistent Disease progression and adverse effects associated with the antibiotic treatment. The prognostic factors for the progression of MAC Pulmonary Disease are low body mass index, poor nutritional status, presence of cavitary lesion(s), extensive Disease, and a positive acid-fast bacilli smear. A regimen consisting of macrolides (clarithromycin or azithromycin) with rifampin and ethambutol has been recommended; this regimen significantly improves the treatment of MAC Pulmonary Disease and should be maintained for at least 12 months after negative sputum culture conversion. However, the rates of default and Disease recurrence after treatment completion are still high. Moreover, treatment failure or macrolide resistance can occur, although in some refractory cases, surgical lung resection can improve treatment outcomes. However, surgical resection should be carefully performed in a well-equipped center and be based on a rigorous risk-benefit analysis in a multidisciplinary setting. New therapies, including clofazimine, inhaled amikacin, and bedaquiline, have shown promising results for the treatment of MAC Pulmonary Disease, especially in patients with treatment failure or macrolide-resistant MAC Pulmonary Disease. However, further evidence of the efficacy and safety of these new treatment regimens is needed. Also, a new consensus is needed for treatment outcome definitions as widespread use of these definitions could increase the quality of evidence for the treatment of MAC Pulmonary Disease.
-
with Mycobacterium Avium Complex Pulmonary Disease
2003Co-Authors: Won-jung Koh, O Jung Kwon, Eun Hae Kang, Ik Soo Jeon, Jang Pyun, Hyoung Suk Ham, Hojoong Kim, Daehee Han, Tae Sung Kim, Kyung Soo LeeAbstract:Background : Mycobacterium avium complex(MAC)is the most common respiratory pathogen in nontuberculous mycobacterial Pulmonary Disease. This study described the clinical characteristics of the patients with Pulmonary Disease caused by MAC. Materials and Methods : The clinical characteristics of 24 patients with Pulmonary Disease caused by the MAC, who fulfilled the 1997 American Thoracic Society diagnostic criteria for nontuberculous mycobacterial Pulmonary Disease, were retrospectively. Results : Fourteen patients(58%) were male and the median age at diagnosis was 61 years(range 46-75). Of the 24 patients, 16 (67%) had a M. intracellulare infection, 7 (29%) had a M. aviuminfection
M. Abdulgany Hamadeh - One of the best experts on this subject based on the ideXlab platform.
-
Sulfasalazine-induced Pulmonary Disease.
Chest, 1992Co-Authors: M. Abdulgany Hamadeh, Janis Atkinson, Lewis J. SmithAbstract:We report the findings in two patients with sulfasalazine-induced Pulmonary Disease. The first patient developed Pulmonary interstitial fibrosis after more than 4 yr of treatment for Crohn's Disease. Pulmonary symptoms and chest roentgenographic and Pulmonary function abnormalities gradually reversed after stopping the drug. No specific treatment was given. The second patient, who had rheumatoid arthritis without Pulmonary Disease, received the drug for 1 yr without experiencing any problems. Readministration seven months later resulted in the development of an acute interstitial Pulmonary Disease. Discontinuing the drug and treatment with corticosteroids produced rapid improvement. We discuss these patients in relation to other reports of sulfasalazine-induced Pulmonary toxicity, highlighting their atypical features.
Naohiko Inase - One of the best experts on this subject based on the ideXlab platform.
-
Serodiagnosis of Mycobacterium avium Complex Pulmonary Disease in Rheumatoid Arthritis
Respiration; international review of thoracic diseases, 2013Co-Authors: Yoshitoshi Komazaki, Yasunari Miyazaki, Toshihide Fujie, Hiroyuki Sakashita, Kimitake Tsuchiya, Meiyo Tamaoka, Yuki Sumi, Yuichiro Maruyama, Toshihiro Nanki, Naohiko InaseAbstract:Background: Mycobacterium avium complex (MAC) Pulmonary Disease (PD) is often difficult and complicated to diagnose or to discriminate from foll
J. Grosset - One of the best experts on this subject based on the ideXlab platform.
-
Sentinel-site surveillance of Mycobacterium avium complex Pulmonary Disease.
The European respiratory journal, 2005Co-Authors: J. Maugein, M. Dailloux, B. Carbonnelle, V. Vincent, J. GrossetAbstract:The incidence of Mycobacterium avium complex (MAC) Pulmonary Disease in HIV-negative patients was studied prospectively from January 1, 2000 to December 31, 2002 through 32 sentinel sites distributed all over France. Among the 275 patients who yielded MAC isolates from respiratory clinical specimens, 101 (36.7%) met the bacteriological, radiographical and clinical criteria established by the American Thoracic Society for nontuberculous mycobacterial respiratory Disease. Of these 101 patients, 81 had underlying lung Disease, mainly previous tuberculosis, bronchectasis or chronic obstructive Pulmonary Disease. Among the 20 patients with no underlying lung Disease, 12 had a predisposing factor such as leukaemia or immunosuppressive treatment and eight had no predisposing factor. All patients with MAC respiratory Disease had clinical symptoms, commonly cough and fatigue, and 52 (51.5%) were sputum smear positive for acid-fast bacillus. The ratio of patients with Mycobacterium avium complex Pulmonary Disease to patients with Pulmonary tuberculosis in France was estimated to be 3% and the incidence of Mycobacterium avium complex Pulmonary Disease in France was 0.2 per 100,000 inhabitants.
